CMX001 is an orally administered lipid conjugate of the synthetic nucleotide analog cidofovir
(CDV). The conjugate is believed to be absorbed in the small intestine then delivered to
target organs throughout the body where it crosses cell membranes by facilitated and passive
diffusion. Inside the cell, CMX001 is cleaved by intracellular phospholipases to release CDV
which is converted to the active antiviral agent, CDV-diphosphate (CDV-PP), by intracellular
anabolic kinases. Adults and adolescents, regardless of viral infection/disease, will have a
maximum weekly dose of 200 mg i.e., 200 mg once weekly OR 100 mg twice weekly; not to exceed
4mg/kg total weekly dose. Pediatric subjects (< 12 years), regardless of viral
infection/disease, will have a maximum weekly dose of 4 mg/kg i.e., 4 mg/kg once weekly OR 2
mg/kg twice weekly.
Stanford is currently not accepting patients for this trial.
For more information, please contact Julia Buckingham, (650) 736 - 1556.
View full details